SCHEMBL24320056

SCHEMBL24320056

CCc1c([N+](=O)[O-])ccc(F)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
FBP1 P09467 3/20 0.44
TSHR P16473 3/20 0.41
CASP6 P55212 1/20 0.40
ATM Q13315 1/20 0.39
HCAR3 P49019 4/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24319574 0.86 ATM (0.38) TDP1L3MBTL1FBP1TSHRCASP6
SCHEMBL7444129 0.81 LMNA (0.47) TDP1L3MBTL1FBP1TSHRCASP6
SCHEMBL21749965 0.80 TDP1 (0.51) TDP1L3MBTL1TSHRCASP6ATM
SCHEMBL13244347 0.79 DHODH (0.39) TDP1ALDH1A1HIF1ACA1CA2
SCHEMBL543983 0.79 TSHR (0.51) TDP1L3MBTL1TSHRCASP6ATM
SCHEMBL633629 0.78 TDP1 (0.46) TDP1L3MBTL1TSHRCASP6ATM
SCHEMBL23539368 0.78 TSHR (0.44) TDP1L3MBTL1FBP1TSHRCASP6
SCHEMBL29154301 0.77 TDP1 (0.45) TDP1L3MBTL1TSHRCASP6ATM
SCHEMBL30635283 0.76 MAPT (0.44) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL1448267 0.76 TDP1 (0.56) TDP1L3MBTL1TSHRCASP6ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-07-24 US disclosed
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-12-31 US disclosed
CN-117062814-A Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use 阿维纳斯运营公司 2023-11-14 CN disclosed
EP-4204418-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2023-07-05 EP disclosed
US-20230081501-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-16 US disclosed
WO-2022047145-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-03-03 WO disclosed
WO-2022047145-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230081501-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF TDP1 1696/4885L3MBTL1 989/4885FBP1 842/4885
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use CRBN, RBX1, ARAF TDP1 1620/4885L3MBTL1 1064/4885FBP1 880/4885
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF TDP1 1696/4885L3MBTL1 989/4885FBP1 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.